AARTIPHARM829.05

Aarti Pharmalabs Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSADVENZYMESAGARWALEYEAKUMSALIVUSAPLLTDCORONAHCGMcap ₹7,516 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity12.3213.698.138.13
Return on Assets8.409.375.025.02
Return on Capital Employed16.5716.7810.4110.41
Return on Invested Capital11.7212.227.018.24
Margins
EBITDA Margin20.8421.9620.2921.65
Operating Margin16.8817.8514.5614.56
Incremental Operating Margin24.6338.09
Pretax Margin16.2217.0512.3613.56
Net Income Margin11.7112.889.6010.82
Net Income to Common Margin11.689.4910.78
FCF Margin0.95-3.33-8.10-8.10
Additional
Effective Tax Rate27.8224.4825.8826.64
Dvd Payout Ratio8.3611.6420.75
Sustainable Growth Rate11.2912.106.448.13
Incremental Operating Margin %24.6338.0933.30
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.